PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting

Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials